Cannabidiol (CBD) is a naturally occurring compound found in the hemp plant (Cannabis sativa) that has generated significant interest in the scientific and medical communities for its interaction with the body’s endocannabinoid system. At The Longevity Center FL, Dr. Benjamin Kosubevsky offers physician-supervised intravenous CBD infusions as an emerging wellness modality for patients in West Palm Beach and across South Florida who are interested in exploring cannabidiol’s potential as part of a broader integrative wellness plan.
CBD is non-psychoactive—it does not produce the “high” associated with THC—and hemp-derived CBD containing less than 0.3% THC is federally legal in the United States under the 2018 Farm Bill. Intravenous delivery of CBD is a newer approach that bypasses gastrointestinal absorption and first-pass liver metabolism, potentially allowing a greater proportion of the compound to reach systemic circulation.
Intravenous cannabidiol (CBD) has NOT been approved by the U.S. Food and Drug Administration (FDA) for the treatment, cure, or prevention of any disease. While the FDA has approved one oral CBD product (Epidiolex®) for specific seizure disorders, no IV CBD formulation has received FDA clearance for any indication. The IV CBD administered at The Longevity Center FL is a hemp-derived product and is not a pharmaceutical drug. Research on intravenous CBD in humans is in its early stages, and the clinical evidence base for IV CBD is limited. This service is offered as an integrative wellness modality under physician supervision and is not intended to replace any standard medical treatment. Results may vary, and no specific health outcomes are promised or guaranteed.
The endocannabinoid system (ECS) is a biological signaling network present throughout the human body that plays a role in regulating a wide range of physiological processes, including mood, sleep, appetite, immune response, and pain perception. The ECS was identified in the early 1990s and has since been described in the peer-reviewed literature as a significant modulator of central nervous system function and overall physiological homeostasis (Pacher et al., Pharmacological Reviews, 2006; Mechoulam & Parker, Annual Review of Psychology, 2013).
CBD interacts with the endocannabinoid system through multiple receptor pathways, including serotonin (5-HT1A), vanilloid (TRPV1), and adenosine receptors, rather than binding directly to the primary cannabinoid receptors (CB1 and CB2) in the way that THC does. This distinct mechanism is believed to underlie CBD’s non-psychoactive profile.
When CBD is taken orally, it undergoes extensive first-pass metabolism in the liver, which significantly reduces its bioavailability—published pharmacokinetic reviews have estimated oral CBD bioavailability at approximately 6–19% depending on formulation and individual factors (Millar et al., Frontiers in Pharmacology, 2018). Intravenous administration bypasses first-pass metabolism entirely, delivering CBD directly into the bloodstream. This route of administration is associated with near-complete systemic availability and a faster onset of effect compared to oral or sublingual delivery.
It is important to note that while the pharmacokinetic advantages of IV delivery are well-understood in general pharmacology, clinical research on IV CBD specifically in humans remains limited. The potential benefits of IV CBD are currently being explored, and the evidence base continues to develop.
CBD is the subject of ongoing scientific investigation across a range of potential applications. The following areas reflect topics of active research in the peer-reviewed literature. These are NOT claims about what CBD IV can do; they represent areas where scientific inquiry is underway:
A peer-reviewed safety analysis has documented that CBD’s most commonly reported adverse effects in clinical studies (primarily oral administration) include drowsiness, changes in appetite, gastrointestinal discomfort, and potential drug-drug interactions—particularly with medications metabolized by the cytochrome P450 enzyme system (Huestis et al., Current Neuropharmacology, 2019). At The Longevity Center FL, all CBD IV infusions are administered under direct physician supervision, with pre-infusion screening for contraindications and post-infusion monitoring.
Patients taking prescription medications—particularly blood thinners, anti-seizure medications, or medications with known CYP450 interactions—should discuss potential interactions with Dr. Kosubevsky before receiving CBD IV.
Before receiving CBD IV, patients meet with Dr. Kosubevsky for a clinical consultation that includes a review of current medications, health history, and wellness goals. This step determines whether CBD IV is appropriate and identifies any potential contraindications.
CBD is administered intravenously over a supervised session in our clinic. The dose is determined by Dr. Kosubevsky based on your individual clinical profile. Patients are monitored throughout the infusion.
Patients are observed for a period following the infusion. Some individuals report a sense of relaxation or calm following the session, though individual experiences vary. Drowsiness may occur, and patients are advised to arrange transportation if needed.
For patients who are interested in incorporating CBD into their wellness plan and want the pharmacokinetic advantages of IV delivery under physician supervision.
For those who have tried oral or sublingual CBD products without the results they were looking for, and who want to explore whether IV delivery may offer a different experience.
For individuals who want the assurance of medical oversight, proper dosing, drug-interaction screening, and post-infusion monitoring rather than self-administering CBD products.
Dr. Benjamin Kosubevsky combines conventional medical training with advanced experience in integrative, regenerative, and osteopathic medicine. For patients interested in CBD IV, Dr. Kosubevsky provides:
Intravenous CBD is a newer modality in integrative wellness. At The Longevity Center FL, it is offered under physician supervision with transparent communication about what the research does and does not yet support. If you are interested in exploring CBD IV as part of your wellness plan, we welcome the opportunity to discuss whether it may be appropriate for you.
Schedule a consultation to discuss whether CBD IV may be appropriate for your wellness goals.
The information on this page is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Intravenous cannabidiol (CBD) has NOT been approved by the U.S. Food and Drug Administration for the treatment, cure, or prevention of any disease or medical condition. The only FDA-approved CBD product is Epidiolex® (oral cannabidiol solution), which is indicated for specific seizure disorders; this is a different product and route of administration than what is described on this page. The IV CBD administered at The Longevity Center FL is a hemp-derived product, not a pharmaceutical drug. Research on IV CBD in humans is in early stages, and the scientific evidence base for this modality is still developing. Individual results and experiences vary. This service is not a substitute for evaluation and care by your primary care physician. CBD may interact with prescription medications, particularly those metabolized by the CYP450 enzyme system; all potential interactions should be discussed with your physician before receiving this therapy. Peer-reviewed research cited on this page reflects preclinical, early-stage clinical, or review-level findings and does not predict individual outcomes. No specific health outcomes are promised or guaranteed.
1. Pacher P, Bátkai S, Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews. 2006;58(3):389-462.
2. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. Annual Review of Psychology. 2013;64:21-47.
3. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology. 2018;9:1365.
4. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836.
5. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology. 2019;17(10):974-989.
Schedule your appointment today and take the first step toward a healthier, more balanced life.
Schedule an Appointment